D J Inwards1, P A Fishkin2, B R LaPlant3, M T Drake3, P J Kurtin4, D A Nikcevich5, D B Wender6, B S Lair7, T E Witzig8. 1. Division of Hematology, Mayo Clinic, Rochester. Electronic address: inwards.david@mayo.edu. 2. Illinois Oncology Research Association, Peoria. 3. Division of Endocrinology, Mayo Clinic, Rochester. 4. Division of Hematopathology, Mayo Clinic, Rochester. 5. Department of Medical Oncology, Essentia Duluth Clinic, Duluth. 6. Department of Oncology, Siouxland Hematology-Oncology Associates, Sioux City. 7. Department of Oncology, Iowa Oncology Research Association, Des Moines, USA. 8. Division of Hematology, Mayo Clinic, Rochester.
Abstract
BACKGROUND: We conducted this trial to determine the maximum tolerated dose (MTD) of temsirolimus added to an established regimen comprised of rituximab and cladribine for the initial treatment of mantle cell lymphoma. PATIENTS AND METHODS: A standard phase I cohort of three study design was utilized. The fixed doses of rituximab and cladribine were 375 mg/m(2) i.v. day 1 and 5 mg/m(2)/day i.v. days 1-5 of a 28-day cycle, respectively. There were five planned temsirolimus i.v. dose levels: 15 mg day 1; 25 mg day 1; 25 mg days 1 and 15; 25 mg days 1, 8 and 15; and 25 mg days 1, 8, 15, and 22. RESULTS: Seventeen patients were treated: three each at levels 1-4 and five at dose level 5. The median age was 75 years (52-86 years). Mantle Cell International Prognostic Index (MIPI) scores were low in 6% (1), intermediate in 59% (10), and high in 35% (6) of patients. Five patients were treated at level 5 without dose limiting toxicity. Hematologic toxicity was frequent: grade 3 anemia in 12%, grade 3 thrombocytopenia in 41%, grade 4 thrombocytopenia in 24%, grade 3 neutropenia in 6%, and grade 4 neutropenia in 18% of patients. The overall response rate (ORR) was 94% with 53% complete response and 41% partial response. The median progression-free survival was 18.7 months. CONCLUSIONS: Temsirolimus 25 mg i.v. weekly may be safely added to rituximab and cladribine at 375 mg/m(2) i.v. day 1 and 5 mg/m(2)/day i.v. days 1-5 of a 28-day cycle, respectively. This regimen had promising preliminary activity in an elderly cohort of patients with mantle cell lymphoma. CLINICALTRIALSGOV IDENTIFIER: NCT00787969.
BACKGROUND: We conducted this trial to determine the maximum tolerated dose (MTD) of temsirolimus added to an established regimen comprised of rituximab and cladribine for the initial treatment of mantle cell lymphoma. PATIENTS AND METHODS: A standard phase I cohort of three study design was utilized. The fixed doses of rituximab and cladribine were 375 mg/m(2) i.v. day 1 and 5 mg/m(2)/day i.v. days 1-5 of a 28-day cycle, respectively. There were five planned temsirolimus i.v. dose levels: 15 mg day 1; 25 mg day 1; 25 mg days 1 and 15; 25 mg days 1, 8 and 15; and 25 mg days 1, 8, 15, and 22. RESULTS: Seventeen patients were treated: three each at levels 1-4 and five at dose level 5. The median age was 75 years (52-86 years). Mantle Cell International Prognostic Index (MIPI) scores were low in 6% (1), intermediate in 59% (10), and high in 35% (6) of patients. Five patients were treated at level 5 without dose limiting toxicity. Hematologic toxicity was frequent: grade 3 anemia in 12%, grade 3 thrombocytopenia in 41%, grade 4 thrombocytopenia in 24%, grade 3 neutropenia in 6%, and grade 4 neutropenia in 18% of patients. The overall response rate (ORR) was 94% with 53% complete response and 41% partial response. The median progression-free survival was 18.7 months. CONCLUSIONS: Temsirolimus 25 mg i.v. weekly may be safely added to rituximab and cladribine at 375 mg/m(2) i.v. day 1 and 5 mg/m(2)/day i.v. days 1-5 of a 28-day cycle, respectively. This regimen had promising preliminary activity in an elderly cohort of patients with mantle cell lymphoma. CLINICALTRIALSGOV IDENTIFIER: NCT00787969.
Authors: A Belch; C T Kouroukis; M Crump; L Sehn; R D Gascoyne; R Klasa; J Powers; J Wright; E A Eisenhauer Journal: Ann Oncol Date: 2006-09-13 Impact factor: 32.976
Authors: David J Inwards; Paul A S Fishkin; David W Hillman; David W Brown; Stephen M Ansell; Paul J Kurtin; Rafael Fonseca; Roscoe F Morton; Michael H Veeder; Thomas E Witzig Journal: Cancer Date: 2008-07-01 Impact factor: 6.860
Authors: Jorge E Romaguera; Luis Fayad; Maria A Rodriguez; Kristine R Broglio; Frederick B Hagemeister; Barbara Pro; Peter McLaughlin; Anas Younes; Felipe Samaniego; Andre Goy; Andreas H Sarris; Nam H Dang; Michael Wang; Virginia Beasley; L Jeffrey Medeiros; Ruth L Katz; Harish Gagneja; Barry I Samuels; Terry L Smith; Fernando F Cabanillas Journal: J Clin Oncol Date: 2005-09-06 Impact factor: 44.544
Authors: T E Witzig; J M Vose; P L Zinzani; C B Reeder; R Buckstein; J A Polikoff; R Bouabdallah; C Haioun; H Tilly; P Guo; D Pietronigro; A L Ervin-Haynes; M S Czuczman Journal: Ann Oncol Date: 2011-01-12 Impact factor: 32.976
Authors: Thomas E Witzig; Susan M Geyer; Irene Ghobrial; David J Inwards; Rafael Fonseca; Paul Kurtin; Stephen M Ansell; Ronnie Luyun; Patrick J Flynn; Roscoe F Morton; Shaker R Dakhil; Howard Gross; Scott H Kaufmann Journal: J Clin Oncol Date: 2005-06-27 Impact factor: 44.544
Authors: Thomas M Habermann; Izidore S Lossos; Glen Justice; Julie M Vose; Peter H Wiernik; Kyle McBride; Kenton Wride; Annette Ervin-Haynes; Kenichi Takeshita; Dennis Pietronigro; Jerome B Zeldis; Joseph M Tuscano Journal: Br J Haematol Date: 2009-02-24 Impact factor: 6.998
Authors: Michael L Wang; Simon Rule; Peter Martin; Andre Goy; Rebecca Auer; Brad S Kahl; Wojciech Jurczak; Ranjana H Advani; Jorge E Romaguera; Michael E Williams; Jacqueline C Barrientos; Ewa Chmielowska; John Radford; Stephan Stilgenbauer; Martin Dreyling; Wieslaw Wiktor Jedrzejczak; Peter Johnson; Stephen E Spurgeon; Lei Li; Liang Zhang; Kate Newberry; Zhishuo Ou; Nancy Cheng; Bingliang Fang; Jesse McGreivy; Fong Clow; Joseph J Buggy; Betty Y Chang; Darrin M Beaupre; Lori A Kunkel; Kristie A Blum Journal: N Engl J Med Date: 2013-06-19 Impact factor: 91.245
Authors: Stephen M Ansell; David J Inwards; Kendrith M Rowland; Patrick J Flynn; Roscoe F Morton; Dennis F Moore; Scott H Kaufmann; Irene Ghobrial; Paul J Kurtin; Matthew Maurer; Christine Allmer; Thomas E Witzig Journal: Cancer Date: 2008-08-01 Impact factor: 6.860
Authors: Thomas E Witzig; Craig Reeder; Jing Jing Han; Betsy LaPlant; Mary Stenson; Han W Tun; William Macon; Stephen M Ansell; Thomas M Habermann; David J Inwards; Ivana N Micallef; Patrick B Johnston; Luis F Porrata; Joseph P Colgan; Svetomir Markovic; Grzegorz S Nowakowski; Mamta Gupta Journal: Blood Date: 2015-04-28 Impact factor: 22.113
Authors: G Hess; U Keller; C W Scholz; M Witzens-Harig; J Atta; C Buske; S Kirschey; C Ruckes; C Medler; C van Oordt; W Klapper; M Theobald; M Dreyling Journal: Leukemia Date: 2015-03-13 Impact factor: 11.528
Authors: Georg Hess; Karola Wagner; Ulrich Keller; Paul La Rosee; Johannes Atta; Kai Hübel; Christian Lerchenmueller; Daniel Schoendube; Mathias Witzens-Harig; Christian Ruckes; Christoph Medler; Christina van Oordt; Wolfram Klapper; Matthias Theobald; Martin Dreyling Journal: Hemasphere Date: 2020-06-08